Thyroid Cancer

Lori J Wirth, ASCO 2018 – Treatment Approaches and Advances in Thyroid Cancer Research

touchONCOLOGY meets with Lori J Wirth from Harvard Medical School and Massachusetts General Hospital in Boston, MA to discuss important treatment approaches and advances for thyroid cancer, including investigating lenvatinib and major findings of the SELECT trial, and how the clinical development of new therapies such as LOXO-292 and spartalizumab may contribute to treatment paradigms […]

Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?

Oncology & Hematology Review, 2017;13(1):21-4 DOI: https://doi.org/10.17925/OHR.2017.13.01.21

Thyroid cancer is the most common endocrine malignancy, and has increased in incidence in recent decades.1–3 Fine-needle aspiration cytology (FNAC) is the mainstay of assessment of thyroid nodules and diagnosis of malignancy.4,5 Several reports have suggested that ultrasound (US)-guided FNAC has many advantages over palpation-guided biopsy. It is now generally recommended that thyroid nodules should […]

Can We Improve Thyroid Fine-needle Aspiration Cytology Adequacy in a Low-volume Thyroid Center?

Oncology & Hematology Review, 2017;13(1): Epub ahead of print

Thyroid cancer is the most common endocrine malignancy, and has increased in incidence in recent decades.1–3 Fine-needle aspiration cytology (FNAC) is the mainstay of assessment of thyroid nodules and diagnosis of malignancy.4,5 Several reports have suggested that ultrasound (US) -guided FNAC has many advantages over palpation-guided biopsy. It is now generally recommended that thyroid nodules […]

Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review

European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51

Tyrosine kinase inhibitors (TKIs) are small anticancer molecules targeting protooncogenic tyrosine kinase signalling pathways.1 TKIs are now therapies used routinely in the treatment of many solid tumours such as gastrointestinal stromal tumour (GIST), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer, breast cancer and non-small-cell lung carcinoma (Table 1). As opposed to cytotoxic […]

Thyroid Cancer—Risks and Causes

Oncology & Hematology Review, 2014;10(2):144–51 DOI: https://doi.org/10.17925/OHR.2014.10.2.144

Thyroid cancer is the most common endocrine cancer, representing about 1 % of all malignancies diagnosed worldwide, with approximately 600,000 men and women alive in the US who have a history of cancer of the thyroid (http://seer.cancer.gov/statfa cts/html/thyro.html). Despite its prevalence, the mortality from thyroid cancer remains relatively low at ~0.5 per 100,000 population per […]

Very Rare Tumours in Paediatric Age – From ‘Tumori Rari in Età Pediatrica’ to the European Cooperative Study Group for Paediatric Rare Tumours

European Oncology & Haematology, 2012; 8(2):130–4 DOI: https://doi.org/10.17925/EOH.2012.08.02.130

Malignant tumours are relatively uncommon in children, especially considering the incidence of cancer in adults. The difficulty of performing meaningful studies due to the limited numbers of patients treated at each paediatric oncology centre has encouraged oncologists to embark on national and international collaboration schemes in order to perform significant research. The positive results achieved […]

Bevacizumab Therapy for Choroidal Melanoma

European Oncology & Haematology, 2012;8(2):101–4 DOI: https://doi.org/10.17925/EOH.2012.08.02.101

In 1971, Folkman formulated the hypothesis that tumour growth and metastasis are angiogenesis-dependent events. 1 Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis. VEGF levels have been demonstrated to be elevated in choroidal melanoma.2,3 However, the use of anti-angiogenic agents such as bevacizumab – a recombinant humanised anti-VEGF monoclonal antibody – has […]

Fifty Years of Progress Against Cancer – The European Organisation for Research and Treatment of Cancer Celebrates its Achievements

European Oncology & Haematology, 2012;8(1):10–13 DOI: https://doi.org/10.17925/EOH.2012.08.01.10

The European Organisation for Research and Treatment of Cancer (EORTC) was founded in 1962 as an international organisation under Belgian law by eminent European oncologists working in the main areas of cancer research. Originally named the Groupe Européen de Chimiothérapie Anticancéreuse (GECA), the organisation changed its name in 1968 and has been known as the […]

The End of Cytotoxics?

European Oncology & Haematology, 2011;7(4):228-233 DOI: https://doi.org/10.17925/EOH.2011.07.04.228

Cancer is characterised by uncontrolled and unlimited multiplication of cells outpacing the natural rate of cell death (apoptosis).1 The treatment of cancer involves cytotoxic or targeted therapeutics that kill the cancer cells, stop their multiplication, inhibit metastasis or break tolerance against cancer cells by modulating T-regulatory cells or antigen-presenting/T-cell recognition via vaccination (see Figure 1).